Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
4.900
+0.260 (5.60%)
At close: Apr 1, 2026, 4:00 PM EDT
5.06
+0.16 (3.34%)
After-hours: Apr 1, 2026, 7:45 PM EDT
Bicycle Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts that cover Bicycle Therapeutics stock have a consensus rating of "Buy" and an average price target of $14, which forecasts a 185.71% increase in the stock price over the next year. The lowest target is $7.00 and the highest is $36.
Price Target: $14 (+185.71%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Bicycle Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 5 | 4 | 4 | 4 | 4 | 5 |
| Hold | 4 | 5 | 5 | 5 | 5 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $44 → $36 | Buy | Maintains | $44 → $36 | +634.69% | Mar 18, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $11 → $7 | Hold | Maintains | $11 → $7 | +42.86% | Mar 18, 2026 |
| Citizens | Citizens | Buy Maintains $12 → $8 | Buy | Maintains | $12 → $8 | +63.27% | Mar 18, 2026 |
| Needham | Needham | Strong Buy Maintains $24 → $15 | Strong Buy | Maintains | $24 → $15 | +206.12% | Mar 18, 2026 |
| Truist Securities | Truist Securities | Hold Initiates $10 | Hold | Initiates | $10 | +104.08% | Nov 24, 2025 |
Financial Forecast
Revenue This Year
30.94M
from 72.59M
Decreased by -57.38%
Revenue Next Year
42.45M
from 30.94M
Increased by 37.20%
EPS This Year
-3.80
from -3.16
EPS Next Year
-3.51
from -3.80
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 63.0M | 129.4M | |||
| Avg | 30.9M | 42.4M | |||
| Low | 3.1M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -13.2% | 318.1% | |||
| Avg | -57.4% | 37.2% | |||
| Low | -95.8% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.56 | -2.38 | |||
| Avg | -3.80 | -3.51 | |||
| Low | -4.63 | -5.29 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.